The administration of denosumab should be via subcutaneous injection only and should not be administered intravenously or intramuscularly. Injection sites include the upper arm, upper thigh, or abdomen. No observation or premedication is required. Dosing is prescribed as 120 mg/1.7 mL (70 mg/mL) solution in a single-dose vial or as a single-use pre-filled syringe containing 60 mg in a 1 mL solution. Administer vitamin D and calcium as necessary to treat or prevent hypocalcemia — no dosing adjustments are required for hepatic or renal impairment. As shown below, the distribution and timing of doses depend on the pathology.

- Skeletal-related events secondary to multiple myeloma or bone metastases from solid tumors: administer 120 mg injection every four weeks.

- Giant cell tumor of bone: 120 mg injection administered every four weeks with supplementary doses of 120 mg on the 8th and 15th day during the first month of treatment.

- Hypercalcemia of malignancy: administer 120 mg injection every four weeks with supplemental doses of 120 mg on the 8th and 15th day during the first month of treatment.

- Osteoporosis/bone loss: administer 60 mg every six months.